A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
Price : $35 *
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ORKA
- 04 Jan 2019 Status changed from recruiting to discontinued.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 15 Mar 2018 New trial record